Other Potential Medical Therapies: The Use of Antiviral Agents to Investigate and Treat Primary Ciliary Cirrhosis

Clinics in Liver Disease

Volumn 12, Issue 2, 2008, Pages 445-460

  Mason, Andrew L ^a   Wasilenko, Shawn T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ALOPECIA; AMYLASE BLOOD LEVEL; BILIARY CIRRHOSIS; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HELICOBACTER PYLORI; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LACTATE BLOOD LEVEL; NAUSEA; NEUTROPENIA; NONHUMAN; PAROTITIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VARIX BLEEDING; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS, BILIARY; MICE;

EID: 43049147086     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.02.006     Document Type: Review

References (78)

1. Xu L., Shen Z., Guo L., et al. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci U S A 100 14 (2003) 8454-8459
2. Sadamoto T., Joplin R., Keogh A., et al. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 352 9140 (1998) 1595-1596
3. Poupon R., and Poupon R.E. Retrovirus infection as a trigger for primary biliary cirrhosis?. Lancet 363 9405 (2004) 260-261
4. Gershwin M.E., and Selmi C. Apocalypsal versus apocryphal: the role of retroviruses in primary biliary cirrhosis. Am J Gastroenterol 99 12 (2004) 2356-2358
5. Mason A., Lindor K., Bacon B., et al. Multi-center, double blind, randomized controlled trial of zidovudine and lamivudine (combivir) therapy for patients with primary biliary cirrhosis. [abstract]. Hepatology 46 4 Suppl 1 (2007) 264A
6. Mason A.L., Farr G.H., Xu L., et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 99 12 (2004) 2348-2355
7. Chen M., Graham D., Girgis S., et al. Combination antiretroviral therapy with combivir attenuates autoimmune biliary disease in the NOD.c3c4 mouse model of primary biliary cirrhosis. [abstract]. Hepatology 46 4 Suppl 1 (2007) 548A
8. Angulo P., Batts K.P., Therneau T.M., et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29 3 (1999) 644-647
9. Combes B., Carithers R.L., Maddrey W.C., et al. A randomized double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22 (1995) 759-766
10. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19 (1994) 1149-1156
11. Lindor K.D., Therneau T.M., Jorgensen R.A., et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. [see comments]. Gastroenterology 110 5 (1996) 1515-1518
12. Poupon R.E., Balkau B., Eschwège E., et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 324 (1991) 1548-1554
13. Poupon R.E., Poupon R., Balkau B., et al. Ursodiol for the long term treatment of primary biliary cirrhosis. N Engl J Med 330 (1994) 1342-1347
14. Gish R.G., and Mason A. Autoimmune liver disease. Current standards, future directions. Clin Liver Dis 5 2 (2001) 287-314
15. Charatcharoenwitthaya P., Pimentel S., Talwalkar J., et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 13 (2007) 1236-1245
16. Guy J.E., Qian P., Lowell J.A., et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 11 10 (2005) 1252-1257
17. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33 1 (2001) 22-27
18. Neuberger J., Gunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10 4 (2004) 488-491
19. Sanchez E.Q., Levy M.F., Goldstein R.M., et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 76 11 (2003) 1583-1588
20. Prince M.I., and James O.F. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 7 4 (2003) 795-819
21. Trigger D.R. Primary biliary cirrhosis: an epidemiological study. Br Med J 281 (1980) 772-775
22. Metcalf J., and James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis 17 1 (1997) 13-22
23. Neuberger J. Primary biliary cirrhosis. Lancet 350 (1997) 875-879
24. Neuberger J.M., Portmann B., MacDougall B., et al. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 306 (1982) 1-4
25. Van-de-Water J., Gerson L.B., Ferrell L.D., et al. Immunohistochemical evidence of disease recurrence following liver transplantation for primary biliary cirrhosis. Hepatology 24 (1996) 1079-1084
26. Leung P.S., Quan C., Park O., et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 170 10 (2003) 5326-5332
27. Selmi C., Balkwill D.L., Invernizzi P., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38 5 (2003) 1250-1257
28. Vergani D., Bogdanos D.P., and Baum H. Unusual suspects in primary biliary cirrhosis. Hepatology 39 1 (2004) 38-41
29. Fujinami R.S., and Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230 4729 (1985) 1043-1045
30. Zhao Z.S., Granucci F., Yeh L., et al. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279 (1998) 1344-1347
31. Mason A., and Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr Gastroenterol Rep 4 1 (2002) 45-51
32. Tanaka A., Prindiville T.P., Gish R., et al. Are infectious agents involved in primary biliary cirrhosis? A PCR approach. J Hepatol 31 4 (1999) 664-671
33. Bachs L., Pares A., Elena M., et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102 6 (1992) 2077-2080
34. Butler P., Hamilton-Miller J.M., McIntyre N., et al. Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut 36 6 (1995) 931-934
35. Ghent C.N., and Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94 2 (1988) 488-493
36. Maddala Y.K., Jorgensen R.A., Angulo P., et al. Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol 99 3 (2004) 566-567
37. Mason A.L., Xu L., Guo L., et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 351 9116 (1998) 1620-1624
38. Xu L., Sakalian M., Shen Z., et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 39 1 (2004) 151-156
39. Liu B., Wang Y., Melana S.M., et al. Identification of a proviral structure in human breast cancer. Cancer Res 61 4 (2001) 1754-1759
40. Hunter E., Casey J., Hahn B., et al. Seventh report of the International Committee on Taxonomy of Viruses (1999), Academic Press, London
41. McDermid J., Chen M., Li Y., et al. Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Aliment Pharmacol Ther 26 (2007) 587-595
42. Selmi C., Ross S.R., Ansari A.A., et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 127 2 (2004) 493-501
43. Etkind P., Du J., Khan A., et al. Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res 6 4 (2000) 1273-1278
44. Ford C.E., Tran D., Deng Y., et al. Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women. Clin Cancer Res 9 3 (2003) 1118-1120
45. Holland J.F., and Pogo B.G. Mouse mammary tumor virus-like viral infection and human breast cancer. Clin Cancer Res 10 17 (2004) 5647-5649
46. Melana S.M., Picconi M.A., Rossi C., et al. Detection of murine mammary tumor virus (MMTV) env gene-like sequences in breast cancer from Argentine patients. Medicina (B Aires) 62 4 (2002) 323-327 [in Spanish]
47. Szabo S., Haislip A.M., Traina-Dorge V., et al. Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences. Microsc Res Tech 68 3-4 (2005) 209-221
48. Wang Y., Go V., Holland J.F., et al. Expression of mouse mammary tumor virus-like env gene sequences in human breast cancer. Clin Cancer Res 4 10 (1998) 2565-2568
49. Wang Y., Holland J.F., Bleiweiss I.J., et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res 55 22 (1995) 5173-5179
50. Wang Y., Pelisson I., Melana S.M., et al. MMTV-like env gene sequences in human breast cancer. Arch Virol 146 1 (2001) 171-180
51. Mant C., and Cason J. A human murine mammary tumour virus-like agent is an unconvincing aetiological agent for human breast cancer. Rev Med Virol 14 3 (2004) 169-177
52. Mant C., and Cason J. Mouse mammary tumor virus and human breast cancer. Cancer Res 65 3 (2005) 1112 [author reply: 1112-3]
53. Mant C., Gillett C., D'Arrigo C., et al. Human murine mammary tumour virus-like agents are genetically distinct from endogenous retroviruses and are not detectable in breast cancer cell lines or biopsies. Virology 318 1 (2004) 393-404
54. Witt A., Hartmann B., Marton E., et al. The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. Oncol Rep 10 4 (2003) 1025-1029
55. Pogo B.G., and Holland J.F. Possibilities of a viral etiology for human breast cancer. Biol Trace Elem Res 56 (1997) 131-142
56. Buetti E., and Diggelmann H. Cloned mouse mammary tumor virus DNA is biologically active in transfected mouse cells and its expression is stimulated by glucocorticoid hormones. Cell 23 2 (1981) 335-345
57. Varmus H.E., Ringold G., and Yamamoto K.R. Regulation of mouse mammary tumor virus gene expression by glucocorticoid hormones. Monogr Endocrinol 12 (1979) 253-278
58. Bentvelzen P. The biology of the mouse mammary tumor virus. Int Rev Exp Pathol 11 (1972) 259-297
59. Bentvelzen P., and Daams J. Mammary-tumor virus activity in brain and liver of GR strain mice. Eur J Cancer 6 (1970) 273-276
60. Reddy A., Prince M., James O.F., et al. Tamoxifen: a novel treatment for primary biliary cirrhosis?. Liver Int 24 3 (2004) 194-197
61. Joplin R., and Gershwin M.E. Ductular expression of autoantigens in primary biliary cirrhosis. Semin Liver Dis 17 2 (1997) 97-103
62. Marshall B.J., Goodwin C.S., Warren J.R., et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of campylobacter pylori. Lancet 2 8626-8627 (1988) 1437-1442
63. Volberding P.A., Lagakos S.W., Koch M.A., et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS clinical trials group of the national institute of allergy and infectious diseases. N Engl J Med 322 14 (1990) 941-949
64. Degott C., Zafrani E.S., Callard P., et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29 (1999) 1007-1012
65. Levy C., and Lindor K.D. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 38 Suppl 1 (2003) S24-S37
66. Oo Y.H., and Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs 64 20 (2004) 2261-2271
67. Mason A., Xu L., and Neuberger J. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis. Am J Gastroenterol 99 12 (2004) 2499-2500
68. Forseter G., Joline C., and Wormser G.P. Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers. Arch Intern Med 154 23 (1994) 2745-2749
69. Mason A.L., and Xu L. RevTree, assignee. Compositions and methods for reverse transcriptase polymerase chain reaction (RT-PCR) of human betaretrovirus (2007), US patent application, No. 2007/0237716
70. Davis G.L. Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 11 Suppl 1 (1990) S72-S77
71. Arner E.S., Spasokoukotskaja T., and Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 188 2 (1992) 712-718
72. Shaw T., and Locarnini S.A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15 4 (1995) 169-184
73. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338 13 (1998) 853-860
74. Cihlar T., Douglas J.L., and Gibbs C.S. Gilead sciences inc., assignee. Methods of inhibition of MMTV-like viruses (2005), US Patent, No. 2005/0220050239753
75. Mason A.L. An autoimmune biliary disease mouse model for primary biliary cirrhosis: something for everyone. Hepatology 44 4 (2006) 1047-1050
76. Irie J., Wu Y., Wicker L.S., et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 203 5 (2006) 1209-1219
77. Koarada S., Wu Y., Fertig N., et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 173 4 (2004) 2315-2323
78. Chen M., Graham D., Zhang G., et al. Biliary infection with mouse mammary tumor virus in the NOD.c3c4 mouse and other mouse models of primary biliary cirrhosis. [abstract]. Hepatology 46 4 Suppl 1 (2007) 551A